Sector News

For pharma marketers, mobile devices reign supreme. But for how long?

November 7, 2021
Life sciences

Pharma marketers take note. Looking for higher click engagement? Run ads Monday and Tuesday. If higher conversion engagement is the goal, though, then it’s Tuesday and Saturday. In terms of the best time—the peak is around 3 p.m. for click engagement and 9 p.m. for conversion, all according to advertising software company Viant Technology.

With healthcare advertising continuing to grow and digital looking to overtake TV ad spending in the future, Viant, which runs programmatic platform Adelphic, studied the data from September 2020 through August 2021.

Thanks to the multitude of moving parts in digital, many marketers are moving to omnichannel platforms allowing for more return on ad spend.

“More and more, what we’re seeing is about 95% of all the campaigns that we have in the pharma vertical are operating on at least two channels—so [Connected TV] plus mobile, or digital out of home and audio and mobile and so forth,” Steven Ohrnstein, Viant’s SVP of platform automation and analytics said.

In fact, three-quarters of all conversions happen on a different device than the original ad impression.

When Google finally fully removes cookies in 2023, there will be a reckoning in digital advertising.

“That will be the official great Apocalypse,” Ohrnstein said, because without cookies there will be no way to target track anything on any device.

So what’s next? Ohrnstein noted that “with the rise of emerging channels, such as Connected Television, it has become increasingly critical for marketers to be able to target and measure at the household level. The future is household-based. It’s more privacy-compliant because we’re moving from a one-to-one personalization to a one-to-some personalization.”

by Sharon Klahr Coey

Source: fiercepharma.com

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).